NASDAQ:CDIO

Cardio Diagnostics Q2 2025 Earnings Results & Report

Cardio Diagnostics logo
$1.60 -0.05 (-3.03%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$1.60 -0.01 (-0.31%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cardio Diagnostics beat analyst earnings expectations but missed on revenue in its Q2 2025 results, released August 14, 2025. The company reported EPS of -$0.97 versus the -$1.80 consensus estimate, while revenue of $10 thousand fell short of the $75 thousand estimate by $65 thousand.

Earnings Announcement Details

Quarter
Q2 2025
Report Date
Time
Before Market Opens

Cardio Diagnostics EPS Results

Actual EPS
-$0.97
Consensus EPS
-$1.80
Beat/Miss
Beat by +$0.83
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 5 quarters

Cardio Diagnostics Revenue Results

Actual Revenue
$10 thousand
Expected Revenue
$75 thousand
Beat/Miss
Missed by -$65.00 thousand
YoY Revenue Growth
N/A

Conference Call Resources

Cardio Diagnostics Q2 2025 Earnings FAQ

Cardio Diagnostics (NASDAQ:CDIO) reported earnings of -$0.97 per share for Q2 2025, beating the consensus estimate of -$1.80. The report was announced on Thursday, August 14, 2025.

Cardio Diagnostics reported revenue of $10 thousand for Q2 2025, against a consensus estimate of $75 thousand.

Cardio Diagnostics Earnings Headlines

Seven bucks, yours for life: my Black Friday indicator deal
Base Camp Trading's Thomas Wood is giving away his proprietary Snapback Indicator for just $7 this Black Friday. Others paid $500 for it. It's a one-time price with no recurring billing, and the indicator is yours for life. It shows when it's time to sell or go short, and when it makes sense to buy. Check it for a potential Snapback before your next trade.tc pixel
See More Cardio Diagnostics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cardio Diagnostics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cardio Diagnostics and other key companies, straight to your email.

About Cardio Diagnostics

Cardio Diagnostics (NASDAQ:CDIO) develops blood-based tests and technology for cardiovascular disease assessment. Its platform combines genetic and epigenetic information with artificial intelligence to support more personalized evaluation of heart disease.

The company’s offerings include Epi+Gen CHD, designed to assess a person’s risk of coronary heart disease, and PrecisionCHD, a test intended to help identify coronary heart disease in people being evaluated for the condition. The tests are designed to complement clinical assessment and are not a substitute for care from a health professional.

Founded in 2017 and based in Chicago, Illinois, Cardio Diagnostics was co-founded by Meesha Dogan, who serves as its chief executive officer. The company focuses primarily on making its testing services available in the United States.

View Cardio Diagnostics Profile